Version 1
: Received: 29 August 2023 / Approved: 29 August 2023 / Online: 30 August 2023 (09:04:04 CEST)
How to cite:
Villanueva, B.H.A.; Tsai, P.; Tayo, L.L. Analysis of Gene Expression Networks in Primary Central Nervous System Tumors for Drug Repurposing Prospects. Preprints2023, 2023082027. https://doi.org/10.20944/preprints202308.2027.v1
Villanueva, B.H.A.; Tsai, P.; Tayo, L.L. Analysis of Gene Expression Networks in Primary Central Nervous System Tumors for Drug Repurposing Prospects. Preprints 2023, 2023082027. https://doi.org/10.20944/preprints202308.2027.v1
Villanueva, B.H.A.; Tsai, P.; Tayo, L.L. Analysis of Gene Expression Networks in Primary Central Nervous System Tumors for Drug Repurposing Prospects. Preprints2023, 2023082027. https://doi.org/10.20944/preprints202308.2027.v1
APA Style
Villanueva, B.H.A., Tsai, P., & Tayo, L.L. (2023). Analysis of Gene Expression Networks in Primary Central Nervous System Tumors for Drug Repurposing Prospects. Preprints. https://doi.org/10.20944/preprints202308.2027.v1
Chicago/Turabian Style
Villanueva, B.H.A., Po-Wei Tsai and Lemmuel L. Tayo. 2023 "Analysis of Gene Expression Networks in Primary Central Nervous System Tumors for Drug Repurposing Prospects" Preprints. https://doi.org/10.20944/preprints202308.2027.v1
Abstract
Primary central nervous system and brain tumors are one of the global burdens that are continuously increasing in cases and requiring more treatment options. Surgery has been the leading treatment option for tumors, however, the localization of the tumor and its infiltrating nature make this option challenging. DNA microarray expression profiles of different CNS tumors provide insight into potential biomarkers for identifying different tumor types and subtypes. Here, we utilized the differentially expressed genes common in four expression profiles, GSE66354, GSE68848, GSE74195, and GSE43290 to reconstruct the gene co-expression network. In this study, we were able to identify preserved cluster genes, hub genes, co-regulating transcription factors, miRNA families, and candidate repurposed drugs. Fourteen identified hub genes, which were, CACNA1A, DNM1, GABRA1, GRIA2, MAPT, SLC17A7, SNAP25, SNAP91, STXBP1, SYT1, COL1A1, COL6A2, FBN2, and FN1 appeared to play a role in tumor progression and may serve as drug targets. We also reported the DEGs in each tumor type, which were ATRT, EPN, PA, MED, PNET, MEN, ACM, ODG, and GBM. Five identified miRNA families, which were, let-7 family, mir-124 family, mir-1 family, mir-103 family, and mir-27 family described in the literature to have tumor-suppressing characteristics. Drug-gene and drug-transcription factor network revealed 32 candidate repurposed drugs and 13 were validated through connectivity map analysis. Here, two main repurposed drugs fit the regulatory requirement for gene interaction, these were, quercetin and vorinostat. Future validation in experimental studies may utilize the future use of the candidate repurposed drugs. Our study provides insights into drug repurposing prospects and understanding tumor expressions.
Keywords
central nervous system tumor; co-expression network; drug repurposing
Subject
Biology and Life Sciences, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
